In this episode of HSS Presents, orthopedic surgeon Dr. Peter K. Sculco sits down with Dr. Fernando Quevedo-González, PhD, to demystify the world of computational modeling and its transformative impact on joint reconstruction. They explore how technologies like finite element analysis allow researchers to break down complex physics into manageable pieces to predict how implants will interact with a patient's unique bone structure. The discussion highlights a future where AI-driven solvers and data from wearable tech could provide surgeons with real-time guidance on the optimal alignment and fixation for every individual. This episode is a must-listen for surgeons and engineers interested in how "digital twins" and predictive analytics are moving from the research lab to the operating room to improve outcomes in complex hip and knee surgeries.

In this episode of HSS Presents, Dr. Carlo Milani is joined by occupational hand therapist Dr. Aviva Wolff to uncover the unique musculoskeletal demands placed on musicians. The discussion challenges the traditional medical approach to vague overuse injuries, advocating instead for a holistic framework that treats musicians as high-performance athletes. From analyzing the biomechanics of instrument positioning to "micro-dosing" rest and correcting scapular instability, Dr. Wolff shares her evidence-based strategies for prevention and longevity. Ideal for providers and performers alike, this episode provides a roadmap for managing the intense physical endurance required for a life in music.

In this episode of HSS Presents, rheumatologist Dr. Caroline Siegel is joined by HSS colleagues Dr. Lisa Sammaritano and Dr. Jane Salmon to discuss managing pregnancy for patients with autoimmune rheumatic diseases. They emphasize that most patients have successful pregnancies, but conditions like systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) carry greater risks, including preeclampsia and placental insufficiency. Successful outcomes rely on preconception planning, which includes achieving quiescent disease for about six months on pregnancy-compatible medications and screening for antibodies. Dr. Salmon also shares exciting clinical trial results using a TNF inhibitor to improve pregnancy outcomes in high-risk APS patients.